FDA Approves Gallium 68 PSMA-11 for PET Imaging in Prostate Cancer

The FDA has approved gallium (Ga) 68 PSMA-11, a radioactive diagnostic agent, for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA)-positive lesions in patients with prostate cancer. Ga 68 PSMA-11 is indicated for patients with suspected prostate cancer metastasis who are eligible for surgery or radiation therapy and for patients who have suspected recurrence based on elevated levels of prostate-specific antigen (PSA). The first drug to be approved specifica...
Continue reading

Vitamin D Supplements for Reducing Advanced Cancer Risk: Paulette Chandler, MD, MPH

In a study recently published in JAMA Network Open, a team of investigators led by Paulette Chandler, MD, MPH, found that vitamin D supplementation is associated with a decreased risk of developing advanced cancer, particularly among individuals with a normal body mass index (BMI). In this interview with i3 Health, Dr. Chandler, an Assistant Professor of Medicine at Harvard Medical School, discusses the significance of these results and the ongoing research investigating vitamin D supplementatio...
Continue reading

Inotuzumab Ozogamicin Effective in Ph-Positive Acute Lymphoblastic Leukemia

In patients with relapsed/refractory Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL), inotuzumab ozogamicin increases rates of response, remission, hematopoietic stem cell transplantation (HSCT), and progression-free survival compared with intensive chemotherapy, although it does not produce a significant improvement in overall survival. "Historically, patients with Ph-positive ALL have had poorer prognoses, with higher rates of relapse and worse long-term survival ...
Continue reading

Atezolizumab for Previously Treated Non-Small Cell Lung Cancer: Julien Mazières, MD, PhD

For patients with previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC), effective treatment options with minimal toxicity remain limited. In this interview with i3 Health, Julien Mazières, MD, PhD, Professor of Respiratory Medicine at Toulouse University Hospital, discusses his collaborative research finding that atezolizumab increases long-term overall survival compared with docetaxel, regardless of histology, subsequent immunotherapy, and programmed death ligand...
Continue reading

Vitamin D Supplements May Reduce the Risk of Developing Advanced Cancer

In individuals without cancer, vitamin D supplementation may decrease the risk of developing advanced cancer, especially for those with a normal body mass index (BMI), according to a recent analysis of a phase 3 trial. "Vitamin D may decrease tumor invasiveness and propensity to metastasize, leading to reduced cancer mortality," write the investigators, led by first author Paulette D. Chandler, MD, MPH, Assistant Professor of Medicine at Harvard Medical School. "Vitamin D may have a role in redu...
Continue reading

Copyright © 2020 Oncology Data Advisor. All rights reserved.